par Depelchin, Pierre 
;Sobolski, John;Jottrand, Maurice ;Flament, C.
Référence Cardiovascular drugs and therapy, 2, 1, page (139-147)
Publication Publié, 1988-05
;Sobolski, John;Jottrand, Maurice ;Flament, C.Référence Cardiovascular drugs and therapy, 2, 1, page (139-147)
Publication Publié, 1988-05
Article révisé par les pairs
| Résumé : | Therapeutic interventions in patients with myocardial infarction, whether during the first hours after coronary occlusion or several days later, aim to reduce mortality and morbidity by several mechanisms: Prevention of fatal ventricular fibrillation, limitation of infarct size, and inhibition of platelet aggregation are some examples of such mechanisms. Results from early intervention trials with beta blocking agents, particularly from ISIS-I, suggest that 1-year mortality is significantly lower in selected patients randomized to active treatment. Late intervention studies also suggest a significant reduction in coronary mortality and morbidity with beta blockade, particularly when data are pooled. Studies with the calcium channel blockers nifedipine and verapamil were unable to demonstrate any beneficial effects of these drugs on mortality or reinfarction. In this review article, attention will be directed to the most recent information about the preventive value of beta adrenergic blocking drugs and slow calcium channel inhibitors. © 1988 Kluwer Academic Publishers. |
